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Abstract
Objective
To determine the relationship between serum serotonin (5-HT) levels, ictal central apnea
(ICA), and postconvulsive central apnea (PCCA) in epileptic seizures.
Methods
We prospectively evaluated video EEG, plethysmography, capillary oxygen saturation (SpO2),
and ECG for 49 patients (49 seizures) enrolled in a multicenter study of sudden unexpected
death in epilepsy (SUDEP). Postictal and interictal venous blood samples were collected after
a clinical seizure for measurement of serum 5-HT levels. Seizures were classified according to
the International League Against Epilepsy 2017 seizure classification.We analyzed seizures with
and without ICA (n = 49) and generalized convulsive seizures (GCS) with and without PCCA
(n = 27).
Results
Postictal serum 5-HT levels were increased over interictal levels for seizures without ICA (p =
0.01), compared to seizures with ICA (p = 0.21). In patients with GCS without PCCA, serum
5-HT levels were increased postictally compared to interictal levels (p < 0.001), but not in
patients with seizures with PCCA (p = 0.22). Postictal minus interictal 5-HT levels also differed
between the 2 groups with and without PCCA (p = 0.03). Increased heart rate was accom-
panied by increased serum 5-HT levels (postictal minus interictal) after seizures without PCCA
(p = 0.03) compared to those with PCCA (p = 0.42).
Conclusions
The data suggest that significant seizure-related increases in serum 5-HT levels are associated
with a lower incidence of seizure-related breathing dysfunction, and may reflect physiologic
changes that confer a protective effect against deleterious phenomena leading to SUDEP. These
results need to be confirmed with a larger sample size study.
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Sudden unexpected death in epilepsy (SUDEP) is second only
to stroke as a leading cause of years of potential life lost in
patients with neurologic disorders.1 Agonal neural pathways,
with or without preceding seizures, are characterized by pro-
found cardiovascular or respiratory dysfunction.2,3 Peri-ictal
breathing compromise includes prolonged ictal central apnea
(ICA),4 and postconvulsive central apnea (PCCA) with or
without bradycardia/asystole.5 Increasing evidence from ani-
mal and human studies suggest that SUDEP-related breathing
dysfunction may involve serotonergic pathways6,7; brainstem
respiratory rhythm generators that control breathing are
stimulated by serotonin (5-HT) brainstem raphe neurons,8
which contribute to respiratory and arousal responses to
hypercapnia.9,10 Serotonergic fibers project to cerebellar Pur-
kinje and deep nuclei, both of which serve to dampen expres-
sion of apnea and blood pressure, with the deep nuclei having
a significant chemosensitive role.11 These midline serotonergic
neurons, in addition to somatostatin and neurokinin-1 receptor
expressing neurons in the ventrolateral medulla, are sub-
stantially reduced in SUDEP patients compared to controls.12
Additional support for brainstem contributions to SUDEP
comes from imaging evidence of significant atrophy in pon-
tomedullary areas known to modulate breathing (a clinical
brainstem marker of seizure severity), tonic posturing during
generalized convulsive seizures (GCS),12,13 and specific neu-
roimaging changes in a SUDEP animal model.14 In a previous
study, increased 5-HT levels from baseline occurred immedi-
ately after seizures in patients but the degree of 5-HT increase
was negatively correlated with the duration of the tonic seizure
phase, suggesting an association between more severe seizures
and lower serotonergic tone in the postictal state.15 In the
current study, we examined the relationship between peri-ictal
central apnea and serum 5-HT levels in the interictal and
postictal phases in patients with intractable epilepsy.
Methods
Standard protocol approvals, registrations,
and patient consents
The study was approved by the Institutional Review Board at
the University Hospital, Cleveland, Ohio. Written informed
consent was provided by all patients enrolled in the research
study.
Patient selection
A prospective cohort of patients with intractable epilepsy aged
18 years and above, admitted to the Epilepsy Monitoring Unit
Glossary
BBB = blood–brain barrier;BMI = bodymass index;GCS = generalized convulsive seizures;HR = heart rate; ICA = ictal central
apnea; PCCA = postconvulsive central apnea; PGES = postictal generalized EEG suppression; SRI = serotonin reuptake
inhibitor; SUDEP = sudden unexpected death in epilepsy; VEEG = video EEG.
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during January 2015 to April 2018, were consented to par-
ticipate in an institutional review board–approvedmulticenter
autonomic and imaging SUDEP biomarker project (National
Institute of Neurological Disorders and Stroke U01-090407)
study. Forty-nine seizures were recorded in 49 patients (1
seizure per patient). Seizures were classified according to the
2017 International League Against Epilepsy seizure classifi-
cation based on the most prominent clinical signs. The seiz-
ures were classified into 2 major groups: GCS, which included
generalized tonic-clonic seizures of genetic generalized epi-
lepsy and focal to bilateral tonic-clonic seizures, and focal
seizures, which did not generalize.
Video EEG (VEEG) and
cardiorespiratory monitoring
Standard surface VEEG using the 10–20 International Elec-
trode System and multichannel ECG were acquired using the
Nihon-Kohden system (Tokyo, Japan). Pulse oximetry was
used to capture peripheral capillary oxygen saturation (SpO2)
and heart rate (HR) (Nellcor OxiMax N-600x, Covidien,
Dublin, Ireland). Chest and abdominal excursions were
recorded using inductance plethysmography (Ambu, Ballerup,
Denmark). Both ICA and PCCA were defined as ≥1 missed
breath based on breathing rhythm in the previous 30 seconds,
with a minimum duration of 5 seconds without alternative ex-
planation (e.g., movement, speech, or intervention). PCCA was
also defined as absence of breathing for at least 5 seconds after
GCS end. In addition, we diagnosed ICA in patients with gen-
eralized onset motor tonic-clonic seizures as cessation of
breathing movements lasting from ≥5 seconds in the absence of
generalized tonic or clonic movements, since such movements
invariably produced movement artifact in breathing channels.
We preferred the term PCCA rather than postictal central apnea
because electrographic seizure discharges continued for varying
durations after convulsions ended in some patients.
Data collection
Phenotypic and electroclinical data were collected, including
sex, age, body mass index (BMI), age at epilepsy onset, epi-
lepsy duration, respiratory comorbidities, cardiac comorbid-
ities, epileptogenic zone, presence and duration of ICA and
PCCA, presence and duration of hypoxemia, sleep state,
baseline (2 minutes before seizure onset) HR, HR at GCS
onset, maximum or minimum HR up to the immediate 3
minutes postictal period based on R-R interval, seizure phase
and duration (tonic, clonic, jittery), and presence and dura-
tion of postictal generalized EEG suppression (PGES). Pos-
tictal and interictal venous blood samples were collected in
serum-separator tubes (Z Serum Sep Clot activator tubes
fromGreiner-Bio-One North America, Inc., Monroe, NC) for
a cleaner separation of serum from blood cells. Since no
commercial assays are available for measuring whole blood
5-HT using platelet-rich and platelet-poor plasma prepara-
tions, we opted for a diagnostic assay to measure the 5-HT
levels in the serum since our objective was to determine if
peripheral levels of 5-HT in the blood change after seizures.
All samples were processed within 30 minutes of collection,
spun down, and serum was frozen. They were shipped in
frozen state by courier to reference laboratory LabCorp
(Burlington, NC; labcorp.com/) for analysis. Serum 5-HT
levels were measured using high-performance liquid chro-
matography with electrochemical detection. The reference
range reported by LabCorp for serum 5-HT was 0–420 ng/
mL. Collection of interictal samples was only carried out after
successful collection of postictal samples at the earliest feasi-
ble time as there was no guarantee of seizure occurrence
during admission. Interictal samples were always obtained at
rest after at least 12 hours since the last recorded clinical
seizure.
Statistical analysis
Statistical analysis was done using SPSS software version 24.0
(IBM, Armonk, NY). Summary statistics were reported as
mean ± SD (range). Statistical significance for intergroup
differences was assessed with the Pearson χ2 test and Fisher
exact test for dichotomous or nominal variables. Mann-
WhitneyU test was used for continuous variables since they
did not follow a normal distribution (Kolmogorov-Smirnov
test). Binary logistic regressions were used to assess the
association between dichotomous variables and other var-
iables and combinations. Kruskal-Wallis H test was used to
determine differences in continuous variables. Spearman
correlation was used to determine correlation between
continuous variables. A nonparametric Wilcoxon paired
t test was used to compare interictal and postictal 5-HT
levels in groups with and without ICA and PCCA. p < 0.05
was considered statistically significant. A multivariate
linear regression analysis was used to model the relation-
ship of change in 5-HT levels with other independent
variables of age, sex, age at epilepsy onset, and time to
postictal blood draw for generalized seizure groups with
PCCA or ICA.
Data availability
The datasets used and analyzed during the current study are
available from the corresponding author on request.
Results
We analyzed a total of 49 seizures (27 GCS, which included
both generalized tonic-clonic seizures of genetic generalized
epilepsy and focal to bilateral tonic-clonic seizures, and 22
focal seizures) in 49 patients (29 female) with mean age of
42.0 ± 14.4 years (range 20–77). Age at epilepsy onset was
25.2 ± 18.4 years, mean epilepsy duration was 16.8 ± 15.1
years, and BMI was 28.9 ± 7.8. ICA was seen in 17/49
(34.7%) seizures whereas PCCA was found in 8/27 (29.6%)
seizures.
Characteristics of patients with and
without ICA
Electroclinical characteristics of seizures in the presence and
absence of ICA are presented in table 1. A total of 12/17
(71%) patients with ICA were female, compared to 17/32
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(53%) in the non-ICA group. Patients with ICA tended to-
wards older age groups, but without statistical significance (p =
0.10). Duration of epilepsy appeared to be shorter for patients
with ICA but not significantly so. BMI was similar in both
groups. However, patients with ICA were older at onset of
epilepsy (p = 0.01).
5-HT levels and ICA in seizures
The relationship between 5-HT levels and ICA is shown in
figure 1. Mean interictal 5-HT levels in patients without ICA
(n = 32) were 109.1 ± 70.1 ng/mL (range 8–343) compared
to 125.8 ± 96.1 ng/mL (range 2–416) in patients with ICA.
Postictal levels in patients without ICA were 139.8 ± 92.2 ng/
mL (range 11–386) compared to 163.0 ± 98.2 ng/mL (range
7–306) in patients with ICA. The rise in postictal serum 5-HT
was seen in both ICA and non-ICA groups but proved sig-
nificant only in the latter (p = 0.01), possibly due to difference
in sample size. There was no significant difference between
the ICA and non-ICA group when interictal levels, postictal
levels, or the postictal to interictal difference in serum 5-HT
were compared.
Average time elapsed between seizure end and postictal 5-HT
blood draw was 5.5 ± 2.9 minutes for those with ICA and 6.7 ±
6.5 minutes for those without ICA (p = 0.32). There was no
correlation between blood draw time and postictal 5-HT
levels or change in 5-HT levels between postictal and inter-
ictal levels in patients with and without ICA.
Table 1 Clinical characteristics of seizures with and without ictal central apnea (ICA)
Demographics ICA (n = 17) No ICA (n = 32) p Value
Sex 0.23
Male 5 (29.4) 15 (47.0)
Female 12 (70.6) 17 (53.0)
Age, y 46.5 ± 14.3 39.6 ± 14.0 0.10
BMI 26.9 ± 6.0 29.9 ± 8.4 0.20
History
Age at epilepsy onset, y 34.2 ± 20.4 20.5 ± 15.5 0.01
Epilepsy duration, y 12.3 ± 12.8 19.2 ± 15.8 0.13
Epileptogenic zone
Generalized — 7 (21.8)
Temporal 14 (82.3) 10 (31.3)
Frontal 2 (11.8) 10 (31.3)
Parietal — 2 (6.3)
Unknown 1 (5.9) 3 (9.4)
Seizure semiologya
Generalized onset motor tonic-clonic 6 (35.3) 12 (37.5)
Focal to bilateral tonic-clonic 3 (17.6) 6 (18.8)
FOIA nonmotor onset 4 (23.5) 4 (12.5)
FOA motor onset automatisms — 3 (9.4)
FOIA motor onset hyperkinetic 4 (23.5) 5 (15.6)
FOIA clonic — 2 (6.3)
Seizure measures
Clinical seizure duration, s 50.4 ± 14.9 55.5 ± 20.7 0.37
ICA duration, s 16.1 ± 11.3 —
ICA blood draw, minutes after seizure end 5.5 ± 2.9 6.7 ± 6.5 0.32
Abbreviations: BMI = body mass index; FOA = focal onset aware; FOIA = focal onset impaired awareness.
Values are given as n (%) or mean ±SD.
a International League Against Epilepsy classification of seizures.
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Characteristics of patients with and
without PCCA
Electroclinical characteristics of patients with GCS in the
presence and absence of PCCA are shown in table 2. Patients
with PCCA (7/8 [87.5%]) were more likely to be female
compared to the non-PCCA group (8/19 [42%]; p = 0.05).
Patients with PCCA tended to be younger, but not signifi-
cantly so. Average age at epilepsy onset was earlier in patients
with PCCA compared to non-PCCA but was not different (p
= 0.16). BMI, duration of epilepsy, and cardiac or respiratory
comorbidities were similar in both groups.
Seizure semiology and epileptogenic zones for both groups
are shown in table 2. The clinical seizure duration was similar
in both groups. SpO2 nadir (%) did not differ between the 2
groups. There was no significant difference between the 2
groups for other clinical features of the seizure including
durations of hypoxemia, tonic phase, clonic phase, jittery
phase, or PGES. There was also no difference in HR at
baseline, generalized clinical onset, or maximum HR within 3
minutes of seizure end. The average time elapsed between
postictal blood draw and seizure end was 11.0 ± 9.3 minutes
for those with PCCA and 7.8 ± 5.1 minutes for those without
PCCA (p = 0.26).
5-HT levels and PCCA in GCS
Postictal central apnea was only seen after GCS and was
referred to as PCCA. In seizures with PCCA, mean interictal
and postictal 5-HT levels were 92.9 ± 69.8 ng/mL (range
16–227) and 124.8 ± 104.9 ng/mL (range 11–306), respectively
(figure 2A). In the non-PCCA group, the mean interictal 5-HT
level was 116.4 ± 62.8 ng/mL (range 8–198) and postictal level
was 189.9 ± 97.8 ng/mL (range 13–386) (figure 2A). The
postictal serum 5-HT levels compared to interictal levels were
higher in the non-PCCA group (p < 0.001) than in PCCA (p
= 0.22) using a nonparametric Wilcoxon paired sample t test.
When PCCA and non-PCCA groups were compared, the
mean changes (postictal minus interictal) in serum 5-HT
were higher in non-PCCA (73.5 ± 59.0 ng/mL) than in
PCCA (31.9 ± 67.5 ng/mL) (figure 2B) using a non-
parametric Mann-Whitney U test (p = 0.03).
5-HT levels with PCCA and ICA in GCS
ICA preceded PCCA in 3/8 GCS (37.5%), as shown in table
2. In the non-PCCA group, there were 6/17 GCS (35.3%)
that had ICA (table 2). In 2 seizures in the non-PCCA group,
ICA could not be reliably commented upon and therefore
were excluded from analysis. Mean ICA duration was 10.3 ±
6.7 seconds for patients with PCCA and 14.5 ± 5.4 seconds for
the non-PCCA group (p = 0.34). There was no significant
difference in comparing postictal serum 5-HT levels or the
difference in postictal to interictal levels between the 2 groups
of GCS with and without ICA.
A multivariate linear regression analysis was performed to
assess the extent to which change in postictal to interictal
5-HT levels reflected the effect of GCS and its relation to
PCCA and ICA. Other variables included in the analysis were
age, sex, age at epilepsy onset, and time to postictal blood
draw. There was no significant association between changes in
serum 5-HT levels and age, sex, age at epilepsy onset, and time
to postictal blood draw for all 3 groups. The prediction sig-
nificance for the whole generalized convulsive seizures group
was p = 0.235, subgroup of generalized seizures with only
PCCA was p = 0.615, and subgroup of generalized seizures
with only ICA was p = 0.710.
5-HT levels and HR in GCS
HR at baseline, generalized clinical onset of seizure, and the
maximum HR within 3 minutes postictally was measured for
all patients with GCS with and without PCCA, as shown in
table 2. The change in serum 5-HT levels (postictal minus
Figure 1 Serum 5-HT levels and ictal central apnea (ICA) after generalized convulsive and focal seizures
The mean serum interictal 5-HT levels are shown in light green bars
and postictal 5-HT levels (ng/mL) are shown in dark green bars for the
2 groups; the left 2 columns without ICA (n = 32) and the right 2
columns with ICA (n = 17). The levels of postictal serum 5-HT in the
absence of ICA was higher when compared to interictal levels (p =
0.01). However, in the presence of ICA, no significance was observed
(p = 0.21).
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Table 2 Clinical characteristics of seizures with and without postconvulsive central apnea (PCCA)
PCCA (n = 8) No PCCA (n = 19) p Value
Demographics
Sex
Male 1 (12.5) 11 (58.0) 0.05
Female 7 (87.5) 8 (42.0)
Age, y 38.0 ± 13.1 43.4 ± 17.3 0.43
BMI 29.9 ± 7.7 27.7 ± 7.4 0.49
History
Age at epilepsy onset, y 16.0 ± 5.9 27.1 ± 21.0 0.16
Epilepsy duration, y 22.0 ± 17.0 16.3 ± 11.3 0.31
Respiratory comorbidities 1 (12.5) 2 (11.0)
Cardiac comorbidities 1 (12.5) 1 (5.0)
Epileptogenic zone
Generalized 2 (25.0) 5 (26.3)
Temporal 1 (12.5) 9 (47.4)
Frontal 4 (50.0) 2 (10.5)
Unknown 1 (12.5) 3 (15.8)
Seizure semiology
Generalized onset motor tonic-clonic 4 (50.0) 7 (36.8)
Focal to bilateral tonic-clonic 4 (50.0) 12 (63.2)
Seizure measures
Clinical seizure duration, s 49.1 ± 17.8 55.4 ± 18.4 0.42
PCCA duration, s 7.1 ± 2.0
SpO2 nadir, % 64.3 ± 14.0 59.2 ± 13.1 (n = 15) 0.39
Presence of hypoxemia 6 (75.0) 11 (58) (n = 18)
Hypoxemia duration 110.6 ± 46.3 (n = 5) 128.4 ± 77.2 (n = 11) 0.64
Tonic phase duration, s 8.7 ± 5.6 (n = 6) 9.8 ± 4.7 (n = 11) 0.67
Jittery phase duration, s 12.9 ± 11.5 (n = 6) 11.7 ± 7.8 (n = 13) 0.79
Clonic phase duration, s 31.4 ± 11.1 (n = 8) 41.7 ± 19.5 (n = 19) 0.18
Sleep state
Awake 4 (50) 7 (37)
Asleep 4 (50) 12 (63)
Baseline HR 78.0 ± 31.0 70.1 ± 13.5 0.78
HR at generalized clinical onset 96.5 ± 29.7 94.3 ± 29.8 0.86
Maximum heart rate within 3 Minutes 154.0 ± 29.5 145.4 ± 15.4 0.31
Presence of PGES 7 (87.5) n = 8 6 (46.2) n = 13
PGES duration, s 32.7 ± 23.1 (n = 7) 34.3 ± 14.8 (n = 6) 0.88
ICA incidence 3 (37.5) (n = 8) 6 (35.3) (n = 17)
Abbreviations:BMI= bodymass index;HR= heart rate; ICA= ictal centralapnea;PGES= postictal generalizedEEGsuppression;SpO2= peripheral capillaryoxygensaturation.
Values are given as n (%) or mean ± SD.
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interictal) was plotted against change in HR (HR at generalized
clinical onset of seizure minus HR at baseline) (figure 3). In
patients without PCCA, an increase in 5-HTwas associated with
an increase in HR (figure 3A; p = 0.03), but not in patients with
PCCA (figure 3B; p = 0.42). The change in serum 5-HT level
was less than 50 ng/mL for the entire PCCA group, except for
one patient at ;200 ng/mL of 5-HT (figure 3B).
Discussion
We previously reported that serum 5-HT levels in GCS were
significantly higher postictally than in the interictal state
compared to focal seizures.15 However, given the critical role
of 5-HT in breathing modulation and arousal,9,10 its influence
on human peri-ictal breathing features is unknown. Here, we
sought to determine the relationship between 5-HT levels and
seizure-related breathing dysfunction and underlying risk
factors associated with SUDEP. In this study, limited to
a small number of patients (n = 49), we found that (1) serum
5-HT levels were significantly higher postictally compared to
the interictal state for patients who did not develop ICA, (2)
serum 5-HT levels were significantly higher postictally com-
pared to interictal levels in patients with GCS who did not
develop PCCA compared to those who developed PCCA,
and (3) higher serum 5-HT levels were positively associated
with increased HR changes in patients without PCCA. We
were able to show that patients with GCS can be separated
Figure 2 Serum 5-HT levels and postconvulsive central apnea (PCCA) after generalized convulsive seizures
(A) Elevated levels of postictal 5-HT in generalized convulsive seizures (GCS). Themean serum interictal 5-HT levels are shown in light green bars and postictal
5-HT levels (ng/mL) are shown in dark green bars for the 2 seizure groups: PCCA (n = 8) andnon-PCCA (n = 19). The levels of postictal serum5-HT in the absence
of PCCA were higher when compared to interictal levels (p < 0.001), but not when PCCA occurred (p = 0.22). (B) Elevated serum 5-HT levels in the absence of
PCCA. The change in 5-HT (postictal minus interictal) was plotted for seizures without PCCA (in gray) and with PCCA (in red). The change in serum 5-HT
(postictal minus interictal levels) was moderate when the 2 groups were compared (p = 0.03).
Figure 3 Association of heart rate (HR) with serum 5-HT
(A) The differences in serum 5-HT levels (postictal minus interictal) were plotted against the change in HR (difference in HR at clinical onset of seizure minus
baseline) for seizures without postconvulsive central apnea (PCCA) (n = 19) shown as blue dots. Increased change in serum 5-HT was associated with an
increase in heart rate (p = 0.03). (B) Similar analysis revealed no association between serum5-HT levels and heart rate for patients with PCCA (n = 8) and shown
as red dots (p = 0.42).
Neurology.org/N Neurology | Volume 93, Number 15 | October 8, 2019 7
Copyright © 2019 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
into a potentially high SUDEP risk group (low postictal 5-HT
levels, presence of PCCA, and low HR). These findings
suggest that serum 5-HT levels may reflect changes in phys-
iology that play a role in the development and potentially the
severity of peri-ictal apneic phenomena and HR responses in
epileptic seizures.
5-HT is a monoaminergic neurotransmitter synthesized
through the actions of 2 different tryptophan hydroxylase
isoforms encoded by the genes TPH1 and TPH2. These are
expressed in intestinal enterochromaffin cells and serotoner-
gic neurons in the brainstem, respectively. Most 5-HT
(>95%) is found outside the CNS. Some of the peripheral
5-HT synthesized by enterochromaffin cells is taken up by
platelets, which express the 5-HT transporter (SERT). The
release of 5-HT from enterochromaffin cells is typically in
response to acetylcholine, raised intraluminal pressure, sym-
pathetic nerve stimulation, and low intestinal pH.16 The ori-
gin of almost all brain 5-HT is a small group of neurons in the
medullary raphe nuclei and midbrain.17 Raphe 5-HT neurons
project throughout the neuraxis and are vital for many brain
functions including mood, sleep/arousal, thermoregulation,
autonomic control, and breathing.17,18
Peripheral (serum) 5-HT does not readily cross the blood–
brain barrier (BBB), which is made up of a single layer of
endothelial cells connected by tight junctions, and acts as
a barrier that prevents exchange of water-soluble substances
between the brain and blood.19 During intense seizure ac-
tivity, such as status epilepticus, BBB permeability increases,
allowing potential exchange of 5-HT between the CNS and
the peripheral circulation.20 BBB dysfunction as a conse-
quence of epileptic seizures was also recently reported using
a newly established quantitative MRI protocol.21 Thus, pe-
ripherally generated 5-HT may pass into the brain due to
seizure-induced disruption of the BBB and add to the stim-
ulatory effects of synaptically released 5-HT on respiration
and arousal.19 The significance of this BBB breakdown and
the extent to which it allows 5-HT transfer remain unclear, but
if breakdown does occur the increase in serum (5-HT) would
be expected to stimulate breathing and arousal.
Patients who undergo SUDEP or near-SUDEP are known to
have profound dysregulation of breathing after generalized
convulsive seizures.6,22,23 Serotonergic raphe neurons in the
brainstem, which play a major role in respiratory chemore-
ception9 and arousal,10 are suspected to play a role in SUDEP
and SIDS.24,25 5-HT2C receptor knockout mice and DBA1/
DBA2 mouse models of seizures and SUDEP exhibit apneic
fatalities in the postictal state if not resuscitated26,27 and death
is preventable with serotonin reuptake inhibitor (SRI) pre-
treatment in these mice.28 In human seizures, SRI treatment
has been found to correlate with reduced severity of ictal
SpO2 decreases,
29 further emphasizing the positive role of
5-HT in seizure-related respiratory phenomena. ICA is usu-
ally brief, self-limited, and benign, and usually occurs as
a semiologic phenomenon in temporal lobe epilepsy,4 as
confirmed in our data. Our findings suggest that it is not
associated with known SUDEP risk factors such as early age at
onset of epilepsy and duration of epilepsy. However, instances
of prolonged ICA of >60 seconds with severe decreases in
SpO2 may confer SUDEP risk. We found that patients who
exhibited significantly increased postictal serum 5-HT com-
pared to the interictal state were less likely to have ICA.
However, whether these increases mitigate SUDEP risk due
to prolonged ICA is uncertain because in this small sample, we
were unable to show any significant correlation between se-
rum 5-HT levels and ICA duration. Further studies are re-
quired to examine this aspect.
PCCA may have greater SUDEP relevance than ICA and has
been associated with near-SUDEP cases as well as SUDEP,
the latter in a case with prospective follow-up.5 PCCA occurs
much less frequently than ICA; the latter is a preconvulsive
phenomenon in focal epilepsy, likely driven by seizure dis-
charges in cortical sites that modulate breathing4,30,31; and is
phenomenologically distinct from PCCA. PCCA, which
usually occurs in the absence of concurrent electrographic
seizure discharge, may be driven by brainstem mechanisms
akin to a pontomedullary Todd paresis–like phenomenon,
rather than cortical phenomena. Significant differences be-
tween postictal and interictal serum 5-HT levels were noted in
patients without PCCA, potentially conferring protection
from this phenomenon in these patients. Patients with PCCA
were unable to produce similar significant postictal increases
in 5-HT. On the basis of our findings, we speculate that large
postictal increases in serum 5-HT (figure 2B) may play a role
in modulation of respiration in these patients, as evidenced by
the above. Alternatively, the increase in serum 5-HT that we
measured may be a surrogate for an increase in brain 5-HT
levels that may depend on similar physiologic mechanisms,
rather than serum 5-HT directly stimulating breathing. Fatal
postictal apnea/bradycardia is well-described in animal32,33
and human2,34 SUDEP. Its mechanisms may differ in different
types of SUDEP, but in Dravet syndrome mice it is due to
a direct effect of hypoxia on cardiac muscle.32 In our study, in
patients without PCCA, an increase in 5-HT was associated
with an increase in HR, but not in patients with PCCA. No
association was seen between changes in 5-HT levels with age,
sex, epilepsy duration, and time to postictal blood draw when
analyzed for the whole group of GCS, the PCCA-only group,
or the ICA-only group, possibly reflecting the small sample
size of the study. Based on 5-HT levels, SpO2 changes, and
PCCA presence, separation of patients into high and low
SUDEP risk groups may be feasible, and larger scale studies to
this effect are warranted.
Neuropathologic examination of SUDEP brainstems12 shows
evidence of structural injury in serotonergic neurons of the
medullary raphe, and somatostatin and neurokinin-1 receptor
neurons in the ventrolateral medulla, where the pre-Bo¨tzinger
complex35 nucleus is located. The latter is an important site
for inspiratory rhythm generation and a key target for the
respiratory stimulation effect of the periaqueductal gray,
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which is strongly implicated as critical in animal and human
SUDEP.14,36 These findings provide potential anatomical
substrates that mediate the breathing and cardiac dysfunction
seen in PCCA and near-SUDEP/SUDEP.
Several issues remain unexplained. It is not clear if the ap-
parent postictal rise in serum 5-HT level reflects a difference
in serum 5-HT that occurs some time prior to seizure (pre-
ictal), which would be independent of the “interictal serum
5-HT” used in our study. It is possible that changes in
interictal/preictal serum 5-HT would even promote occur-
rence of seizures through various mechanisms (including
change in vigilance), explaining why the apparent postictal
serum 5-HT levels would be increased compared to “interictal
serum 5-HT.” How serum 5-HT levels reflect neuronal 5-HT
activity is unknown, despite the possibility that a permeable
BBB in the seizure state allows serum 5-HT egress into the
CNS.20,37 Future studies on this issue are needed. The pos-
tictal increase in serum 5-HT levels in patients with GCS can
be explained by the observation that serum 5-HT elevations
occur in both humans and horses after moderate to intensive
exercise16,38; physical exertion triggered by GCS may be akin
to muscular activity encountered during exercise and may
have a similar effect on 5-HT levels. However, the finding that
patients with PCCA do not exhibit larger postictal 5-HT
increases is not consistent with this mechanism. Apneic
patients tended to slightly delay postictal blood draws, al-
though not significantly so. Significant elevation in serum
5-HT (which has a half-life of 3 days)39,40 compared to
baseline is recorded as long as 35 minutes after intensive
exercise in humans,38 and differences between PCCA and
non-PCCA groups remained even when the outlying patients
were excluded from analysis. It is possible that patients
without PCCA possess greater platelet reserves of 5-HT,
possibly reflecting increased gut synthesis. In this context,
consideration of differences in gut microbiota in the epilepsy
population may be pertinent, since enterochromaffin cells of
the intestine are the major source of serum 5-HT synthesis,
and gut microbiota are known to regulate host 5-HT bio-
synthesis as well as affect platelet function.41
Our study, with its small sample size of 49 patients, has several
limitations, and our inferences are based on a number of
assumptions. Not least of these is the timing of blood draws.
Our study design was pragmatic, and thus to lessen cost,
interictal samples were taken at an assumed baseline state
after seizures had occurred, rather than before. We also did
not take serial postictal samples at designated time points,
again due to cost and logistical reasons. Nonetheless, our
findings indicate that low levels of postictal serum 5-HT are
associated with potentially deleterious breathing phenomena
and warrant further large-scale study.
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